Phosphodiesterase III inhibitors for heart failure

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2005, Pages

  Amsallem, Emmanuel ^a   Kasparian, Christelle ^b   Haddour, G ^c   Boissel, Jean Pierre ^c   Nony, Patrice ^d  

^a Quality Evaluation Etudes   (France)

^b UNIVERSITÉ LYON 1   (France)

^c LOUIS PRADEL HOSPITAL   (France)

^d HÔPITAL NEUROLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; META ANALYSIS; MORTALITY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, ORAL; HEART FAILURE, CONGESTIVE; HUMANS; PHOSPHODIESTERASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS;

EID: 18944403004     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002230.pub2     Document Type: Review

References (141)

1. Massie B, Bourassa M, Dibianco R, Hess M, Konstam M, Lifoff M et al for the Amrinone Multicenter Trial Group. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a muticenter controlled trial. Circulation 1985;71:963-71.
2. Massie B, Bourassa M, Dibianco R, Hess M, Krebs C, Lifoff M et al for the Amrinone Multicenter Study Group. Multicenter controlled trial of oral amrinone in congestive heart failure: lack of benefit compared to placebo. Journal of the American College of Cardiology 1985;5:514 (abstr).
3. Bergler-Klein J, Globits S, Stefenelli T, Mayr H, Porenta G, Sochor H, et al. Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure [Pimobendan (UDCG 115 BS) in der Langzeittherapie der chronischen Herzinsuffizienz]. Zeitschrift fur Kardiologie 1992;81(10):546-52.
4. Cowley AJ, McEntegart DJ. Placebo-controlled trial of flosequinan in moderate heart failure. The possible importance of aetiology and method of analysis in the interpretation of the results of heart failure trials. International Journal of Cardiology 1993;38(2):167-75.
5. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators. British Heart Journal 1994;72(3):226-30.
6. Dies F, Mcnay JL, Andrejasich CM, Burke PJ, Enas NH. Indolidan (a new phosphodiesterase inhibitor) in chronic heart failure. Circulation 1989;80(suppl II):II-175 (abstr 0698).
7. Uretsky BF, Jessup M, Konstam MA, Benotti JR, Sandberg JA, Dec GW et al for the Enoximone Study Group. Multicenter trial of oral enoximone in patients with moderately severe congestive heart failure: lack of benefit compared to placebo. Circulation 1989;80(suppl II):II-174 (abstr 0694).
8. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J et al for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation 1990;82:774-780.
9. The EPOCH Study Group. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circulation Journal 2002;66(2):149-57.
10. Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Greenberg MA, Rahko PS, et al. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. American Journal of Cardiology 2000;36(2):501-8.
11. Schleman MM, for the enoximone study group. Double-blind placebo-controlled 12 week trial of low dose enoximone in patients with mild to moderate congestive heart failure. Circulation 1991;84(suppl II):II-243 (abstr 0967).
12. Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin ML, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Circulation 1993;88(2):492-501.
13. Goldberg AD, Nicklas J, Goldstein S. Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group. The American Journal of Cardiology 1991;68(6):631-6.
14. Goldberg AD, Nicklas J, Goldstein S, Ford H. Multicenter trial of imazodan in patients with chronic congestive heart failure. European Heart Journal 1990;11:132 (abstr 677).
15. Golderg AD, Goldstein S, Nicklas J. Mulicenter trial of imazadan in patients with chronic congestive heart failure. Circulation 1990;82(suppl III):III-673 (abstr 2673).
16. Lardoux H, Trimarco B, Granier G, Marcadet O, Dubois-Rande JL, Tarral A. Multicentric, double blind and controlled study of oral enoximone (MDL 17043) in chronic heart failure. Circulation 1987;76(suppl IV):IV-179 (abstr 0711).
17. Di Bianco R, Shabetai R, Kostuk W, Moran J, Schlant R, Wright R. Oral milrinone and digoxin in heart failure: results of a placebo-controlled, prospective trial of each agent and the combination. Circulation 1987;76(suppl IV):IV-256 (abstr 1020).
18. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. New England Journal of Medicine 1989;320(11):677-83.
19. OPC-8212 Multicenter Research Group. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovascular Drugs and Thearpy 1990;4:419-26.
20. Just H, Hjalmarsson AC, Remme WJ, Heinrich-Nols J, Dumont JM, Seed P et al on behalf of the pimobendan in congestive heart failure (PICO) investigators. Pimobendan in congestive heart failure: results of the PICO trial. Circulation 1995;92(Suppl I):I-722 (abstr 3469).
21. Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich-Nols J, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996;76(3):223-31.
22. Gollub SB, Kubo SH. Beneficial effects of pimobendan in patients with chronic heart failure: results of a multicenter trial. Circulation 1991;84(suppl II):II-312 (abstr 1241).
23. Kubo SH, Gollub S, Bourge R, Rahko P, Cobb F, Jessup M et al for the Pimobendan Multicenter Research Group. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. Circulation 1992;85:942-9.
24. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: eliability and validity during a randomized, double placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. American Heart Journal 1992;124(4):1017-25.
25. Eichhorn EJ, Tandon PK, DiBianco R, Timmis GC, Fenster PE, Shannon J, et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. Journal of the American College of Cardiology 1993;21(3):634-40.
26. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM et al for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. New England Journal of Medicine 1991;325:1468-75.
27. Packer M, Francis GS, Abrams J, Cobb FR, Eichhorn EJ, Giles TD et al and the PROMISE investigators and coordinators. Oral milrinone increases the risk of sudden death in severe chronic heart failure: the PROMISE trial. Circulation 1991;84(suppl II):II-310 (abstr 12434).
28. Teerlink JR, Jalaluddin M, Anderson S, Kukin ML, Eichhorn EJ, Francis G, et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation 2000;101(1):40-6.
29. Binkley PF, Nunziata E, Cody RJ. Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration. American Heart Journal 1994;128:1147-56.
30. Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, et al. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. Journal of the American College of Cardiology 1993;22(1):65-72.
31. Pitt B, on behalf of the REFLECT II Study Group. A randomized, multicenter, double-blind placebo controlled study of the efficacy of Flosequinan in patients with chronic heart failure. Circulation 1991;84(suppl II):II-311 (abstr 1238).
32. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. New England Journal of Medicine 1998;339(25):1810-6.
33. Carson PE, Colucci WS, Deedwania PC, Uresky BF, Bristow MR, Feldman AM, et al. Lack of proarrhythmia reduction by vesnarinone in advanced heart failure. Circulation 1993;88(suppl I):I-602 (abstr 3240).
34. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM et al for the vesnarinone study group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. New England Journal of Medicine 1993;329:149-55.
35. Narahara KA, and the Western Enoximone Study Group. Enoximone versus placebo: a double-blind trial in chronic congestive heart failure. Circulation 1989;80(suppl II):II-175 (abstr 0695).
36. Narahara KA, and the Western Enoximone Study Group. Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. AmericanHeart Journal 1991;121:1471-9.
37. Assmann I, Kassel P, Duck HG, Fiehring H, Morgan P, Schmidt PKH, et al. Akut-und langzeiteffekte von pimobendan (UD-DG 115) bei herzinsuffizienz NYHA II und III. Ergebnisse einer randomisierten multizentrischen doppelblindstudie. Zeitschrift fur Kardiologie 1991;80:687-94.
38. Banning AP, Ramsey MW, Jones EA, Evans W, Carolan G, Jones CH, et al. Flosequinan in chronic heart failure: how is exercise capacity improved?. European Journal of Clinical Pharmacology 1996;51:133-8.
39. Binkley PF, Shaffer PB, Ryan JM, Leier CV. Augmentation of diastolic function with phosphodiesterase inhibition in congestive heart failure. The Journal of Laboratory and Clinical Medicine 1989;114(3):266-71.
40. Corder CN, Puls A, Wilson M. Clinical effect of indolidan in congestive heart failure. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1992;30:405-9.
41. Cowley AJ, Fullwood L, Stainer K, Hampton JR. Exercise tolerence in patients with heart failure - how should it be measured?. International Journal of Cardiology 1989;24(3):311-6.
42. Cowley AJ, Fullwood L, Stainer K, Hampton JR. Exercise tolerance in patients with heart failure - how should it be measured?. European Heart Journal 1991;12(1):50-4.
43. Crawford MH, Deedwania P, Massie B, Rogers W, Smith G, Dae M, et al. Comparative efficacy of enoximone versus captopril in moderate heart failure. Circulation 1989;80(suppl II):II-175 (abstr 0695).
44. Dibianco R, Shabetai R, Silverman B, Leier C, Benotti J, Silverman ME, et al. Oral amrinone for congestive heart failure: preliminary results of a multicenter double blind and placebo controlled withdrawal. Journal of the American College of Cardiology 1983;1:675 (abstr).
45. DiBianco R, Shabetai R, Silverman BD, Leier CV, Benotti JR, with the Amrinone Multicenter Study Investigators. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. Journal of the American College of Cardiology 1984;4:855-66.
46. Dickstein K, Gauthier DF, Hartley LH, Colucci WS. Effect of IV milrinone on submaximal exercise endurance in heart failure. Circulation 1990;82(suppl III):III-324 (abstr 1285).
47. Dubourg O, Delorme G, Hardy A, Beauchet A, Tarral A, Bourdarias JP. Placebo-controlled trial of oral enoximone in end-stage congestive heart failure refractory to optimal treatment. International Journal of Cardiology 1990;28(suppl 1):S33-42.
48. Elborn JS, Stanford CF, Nicholls DP. Effect of flosequinan on exercise capacity and symptoms in severe heart failure. British Heart Journal 1989;61(4):331-5.
49. Elborn JS, Riley M, Stanford CF, Nicholls DP. The effects of flosequinan on submaximal exercise in patients with chronic cardiac failure. British Journal of Clinical Pharmacology 1990;29(5):519-24.
50. Evans JR, Pacht K, Huss P, Unverferth DV, Bashore TM, Leier CV. Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study. International Journal of Clinical Pharmacology Research 1984;4(1):9-18.
51. Feldman AM, Baughman KL, Lee WK, Gottlieb SH, Weiss JL, Becker LC, et al. Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy. The American Journal of Cardiology 1991;68:1203-10.
52. Galinier M, Massabuau P, Fourcade J, Rochiccioli JP, Puel J, Bounhoure JP. Hemodynamics effects of enoximone in severe congestive heart failure with low cardiac output. European Heart Journal 1989;10:76 (abstr P365).
53. Gilbert E. Double-blind, placebo-controlled (P), comparison of enoximone (E) and dobutamine (D) infusions in moderate to severe congestive heart failure patients (NYHA III-IV). Journal of the American College of Cardiology 1991;17:274A (abstr 245).
54. Haas GJ, Binkley PE, Leier CV. Chronic vasodilator therapy with flosequinan in congestive heart failure. Clinical Cardiology 1990;13(6):414-20.
55. Hori M, Sato H, Ozaki H, Inoue M, Naka M, Fukunami M, et al. Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: a double-blind placebo-controlled study. Heart Vessels 1992;7(3):133-40.
56. Huanqlong Z, Shan W, Dejla H, Xingbin L, Yuan F. Response to milrinone treatment in patients with chronic congestive heart failure. J WCUMS 2000;31:246-7.
57. Jondeau G, Dubourg O, Delorme G, Chikli F, Dumas C, Bock F, et al. Is there any indication for oral phosphodiesterase inhibitor today?. Journal of the American College of Cardiology 1993;21:377A (abstr 800-2).
58. Karlsberg RP. Milrinone is superior to dobutamine in heart failure complicating myocardial infarction. Circulation 1992;86(suppl I):I-808 (abstr 3214).
59. Katz SD, Forman R, Giustino SR, Sonnenblick EH, Le Jemtel TH. Double-blind, randomized evaluation of pimobendan, a new inotrope and vasodilator agent for refractory heart failure. Circulation 1987;76(supll IV):IV-178 (abstr 0707).
60. Katz SD, Kubo SH, Jessup M, Brozena S, Troha JM, Wahl J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. American Heart Journal 1992;123(1):95-103.
61. Khalife K, Zannad F, Brunotte F, Belhadj K, Juilliere Y, Iannascoli F, et al. Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation. American Journal of Cardiology 1987;60(5):75C-79C.
62. Kneissl GD, Scholz M, Dieterich HA, Bubmann WD. Efficacy of enoximone in comparison with captopril in congestive heart failure. European Heart Journal 1990;11:20 (abstr 117).
63. Konstam MA, Benotti JR, Biddle T, Creager MA, Faxon DP, Firth BG, et al. Multicenter comparison of milrinone and dobutamine in congestive heart failure. Circulation 1985;72(supll III):III-201 (abstr 803).
64. Leier CV, Meiller SEL, Binkley PF, Unverferth DV. Regional hemodynamic effects of enoximone in congestive heart failure. Circulation 1987;76(suppl IV):IV-255 (abstr 1017).
65. Leier CV, Lima JJ, Meiler SE, Unverferth DV. Central and regional hemodynamic effects of oral enoximone in congestive heart failure: a double-blind, placebo-controlled study. American Heart Journal 1988;115(5):1051-9.
66. Leier CV, Binkley PF, Starling RC, Huss-Randolph P. Disparity between improvement in left ventricular function and changes in clinical status and exercise capacity during chronic enoximone therapy. American Heart Journal 1989;117(5):1092-8.
67. Likoff MJ, Weber KT, Andrews V, Janicki JS, Wilson H, Rocci ML Jr. Milrinone in the treatment of chronic cardiac failure: a controlled trial. American Heart Journal 1985;110(5):1035-42.
68. Orie JE, Rahko PS, Brookfield L, Gorwit J, McKiernan T. A double blind comparison of enoximone (Enox) and Captopril (Cap) in CHF. Circulation 1989;80(suppl II):II-175 (abstr 0686).
69. Pilcher J, Choraria SK, Taylor DN. Enoximone (MDL 17043) and left ventricular function. A placebo controlled trial. Circulation 1985;72(suppl III):III-404 (abstr 1616).
70. Raw K, Patel J, Mitha A, Chun R, Baragwanath JD. Amrinone vs dobutamine in congestive heart failure due to dilated cardiomyopathy - differences in hemodynamic effects and therapeutic implications. European Heart Journal 1989;10:386 (abstr P2124).
71. Remme MW, Krayenbuhl HP, Frick H, Haehl M, Nehmiz G for the European Pimobendan-Enalapril study group. Discordant hemodynamic and clinical efficacy of enalapril in moderate heart failure. Is pimobendan superior?. European Heart Journal 1992;13:345 (abstr P 1896).
72. Rettig G, Sen S, Frohlig G, Schieffer H, Bette L. Withdrawal of long-term amrinone therapy in patients with congestive heart failure: a placebo controlled trial. European Heart Journal 1986;7:628-631.
73. Ruegg PC, Salzmann R, Alther S. Assessment of a new inotropic agent, DPN 205-734, by means of systolic time intervals (STIs) in healthy volunteers. European Heart Journal 1987;8(suppl 2):abstr 184.
74. Schoeller R, Bruggemann T, Vohringer H, Nothel T, Opitz C, Schroder K, et al. Long-term oral administration of milrinone for dilated cardiomyopathy. Journal of the American College of Cardiology 1986;7:108A.
75. Sridhara BS, Senior R, Anagnostou E, Kinsey C, Lahiri A. Saterinone, a dual-action drug ofr the management of congestive heart failure. European Heart Journal 1994:36 (abstr 393).
76. Voelker W, Mauser M, Preisack M, Karsch KR. Acute hemodynamic effects of abidendan, a new phosphodiesteras inhibitor, in patients with severe heart failure. European Heart Journal 1989;10:387 (abstr 2126).
77. Weber PW, Kupper W, Hamm CW, Heitmann NB, Heitmann NB, Bleifeld W. Acute hemodynamic effects of saterinone in patients with severe chronic heart failure. European Heart Journal 1990;11:19 (abstr 113).
78. Yoshikawa T, Baba A, Suzuki M, Yokozuka H, Okada Y, Nagami K, et al. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group. The American Journal of Cardiology 2000;85(12):1495-7 (A7).
79. Zipperle G, Butzer F, Dieterich HA, Heinrich F. A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure. The American Journal of Cardiology 1987;60(5):72C-74C.
80. Golderg AD, Goldstein S, Nicklas J, for the Imazodan Study Group. Multicenter trial of imazadan in patients with chronic congestive heart failure. Circulation 1990;82(suppl III):III-673 (abstr 2673)a.
81. Kato K, Yasuda K, Isuka M, Sukimoto T, Kimata S, Taniguchi K, et al. Evaluation of the efficacy and safety of pimobendan (UD-CG 115 BS) in treatment of chronic heart failure. A multicenter placebo-controlled, double-blind study. Rinsho Iyaku 1992;8:1311-51b.
82. Kato K, Yasuda K, Kawai C, Kumada T, Sugimoto T, Kimata S, et al. Clinical efficacy of pimobendan for patients with chronic heart failure. A dose-finding study by a multicenter double-blind comparison trial. Rinsho Iyaku 1991;7:2643-9a.
83. Colucci WS, Sonnenblick EH, Adams KF, Berk M, Brozena SC, Cowley AJ, et al. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators. Journal of the American College of Cardiology 1993;22(4 suppl A):113A-8Aa.
84. Colucci WS, Sonnenblick EH, for the milrinone multicenter trials investigators. Oral milrinone as adjunctive therapy for CHF. Circulation 1991;84(suppl II):II-243a.
85. Hansen MS, Stanton EB, Gaward Y, Packer M, Pitt B, Swedberg K et al for the Canadian PROFILE Investigators. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. The American Journal of Cardiology 2002;90:969-73.
86. Moe GW, Rouleau JL, Charbonneau L, Proulx G, Arnold JM, Hall C, et al. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. American Heart Journal 2000;139(4):587-95.
87. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M and the PROFILE investigators & Coordinators. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation 1993;88(suppl I):I-301 (abstr 1612).
88. EMOTE. http://investor.myogen.com/news/20040429-134186.cfm Accessed November 2004.
89. EMOTE. http://www.uihealthcare.com/depts/uiheartcare/clinicaltrials.html#emote [accessed on 04-03-2003].
90. ESSENTIAL. http://clinicaltrials.gov/ct/gui/show/NCT00051285;jsessionid=9722D918B064FF37F8B0D5D470A1B3F1?order=3 [accessed on 04-03-2003].
91. Baptista J, Pike MC. Exact two-sided confidence limits for the odds ratio in a 2 x 2 table. Algorithm AS 115. Applied statistics 1977;26:214-20.
92. Boissel JP, Blanchard J, Panak E, Peyrieux JC, Sacks H. Considerations for the meta-analysis of randomized clinical trials. Summary of a panel discussion. Controlled Clinical Trials 1989;10:254-81.
93. Braunwald E. ACE inhibitors - a cornerstone of the treatment of heart failure. New England Journal of Medicine 1991;325:351-3.
94. Chatterjee K, Parmley WW. Vasodilator therapy for chronic heart failure. Annual Review of Pharmacology and Toxicology 1980;20:475-80.
95. Chesebro JH, Browne KF, Fenster PE, Garland WT, Konstam MA, for the Milrinone Research Group. The hemodynamic effects of chronic oral milrinone therapy: a multicenter controlled trial. Journal of the American College of Cardiology 1988;11:144A.
96. Dargie HJ, Lechat P. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
97. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
98. Cohn JN. Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation 1973;48:5-8.
99. Cohn JN, Franciosa JA. Vasodilatator therapy of cardiac failure. New England Journal of Medcine 1977;297:254-7.
100. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. New England Journal of Medicine 1986;314:1547-52.
101. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New England Journal of Medicine 1991;325:303-10.
102. Colucci WS. Cardiovascular effects of milrinone. American Heart Journal 1991;121:1945-7.
103. The CONSENSUS Trial Study Group. Effects of Enalapril on mortality in severe congestive heart failure. New England Journal of Medicine 1987;316:1429-35.
104. Curfman GD. Inotropic therapy for heart failure - an unfulfilled promise. New England Journal of Medicine 1991;325:1509-10.
105. Der Simonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
106. DiBianco R. Acute positic inotropic intervention: the phosphoesterase inhibitors. American Heart Journal 1991;121:1871-5.
107. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
108. Feldman MD, Copelas L, Gwathmey JK, Philips P, Warrn SE. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987;75:331-9.
109. Fleiss J. Statistical methods for rates and proportions. New York: Wiley, 1973.
110. Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic congestive heart failure. American Journal of Cardiology 1988;62:41A-5A.
111. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Statistics in Medicine 1988;7(8):889-94.
112. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-6.
113. Gilfrich HJ, Dieterich HA. Tolerance of enoximone in patients with heart failure. Zeitschrift fur Kardiologie 1991;80(suppl 4):93-7.
114. Hood WB. Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine. American Journal of Cardiology 1989;63:46A-53A.
115. Katz AM. Cardiomyopathy of overload: a major determinant of prognosis in congestive heart failure. New England Journal of Medicine 1990;322:100-10.
116. LeJemtel TH, Keung E, Ribner HS, Wexler J, Blaufox MD, Sonnenblick EH. Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure. American Journal of Cardiology 1980;45:123-9.
117. Ludmer PL, Wright RF, Arnold JML, Ganz P, Braunwald E, Colucci WS. Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation 1986;73:130-7.
118. Mancini D, LeJemtel T, Sonnenblick E. Intravenous use of amrinone for the treatment of the failing heart. American Journal of Cardiology 1985;56:8B-15B.
119. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22:719-48.
120. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Effect of metoprolol CR/XL in chronic heart failure. Lancet 1999;353:2001-7.
121. Mikulic E, Cohn JN, Franciosa JA. Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure. Circulation 1977;56:528-33.
122. Mulrow CD, Mulrow JP, Linn WD, Aguilar C, Ramirez G. Relative efficacy of vasodilator therapy in chronic congestive heart failure. Implications of randomized trials. JAMA 1988;259:3422-6.
123. Nony P, Boissel JP, Lievre M, Cucherat M, Haugh MC, Dayoub G. Introduction à la méthodologie méta-analytique. Revue de Medecine Interne 1995;16:536-46.
124. Nony P, Cucherat M, Haugh MC, Boissel JP. Standardization of terminology in meta-analysis: a proposal for working definitions. Fundamental & Clinical Pharmacology 1997;11:481-93.
125. Nony P, Cucherat M, Boissel JP. Implication of evidence-based medicine in prescription guidelines taught to French medical students: current status in the cardiovascular field. Clinical pharmacology and Therapeutics 1999;66:173-84.
126. Packer M, Medina N, Yushak M. Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation 1984;70:1038-47.
127. Packer M. Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure. European Heart Journal 1988;9(suppl h):105-8.
128. Packer M. Vasodilator and inotropic drugs for chronic heart failure: distinguishing hype from hope. The American Journal of Cardiology 1988;12:1299-317.
129. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. New England Journal of Medicine 2001;344:1651-8.
130. Peto R. Clinical trial methodology. Biomedicine 1978;28:24-36.
131. Rosenthal R. The "file drawer" problem and tolerance for null results. Psychol Bull 1979;86:638-41.
132. Simonton CA, Chatterjee K, Cody RJ, Kubo SH, Leonard D, Daly P, et al. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. Journal of the American College of Cardiology 1985;6:453-9.
133. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine 1991;325:293-302.
134. Storstein L. Non-receptor-mediated inotropic drugs. European Heart Journal 1988;9:91-3.
135. Tukey JW. Some thoughts on clinical trials, especially problems of multiplicity. Science 1977;198:679-84.
136. Weber KT, Gill SK, Janicki JS, Maskin CS, Jain MC. Newer positive inotropic agents in the treatment of chronic cardiac failure. Current status and future directions. Drugs 1987;33:503-19.
137. Wilmshurst PT, Walker JM, Fry CH, Mounsey JP, Twort CHC, Williams BT, et al. Inotropic and vasodilator effects of amrinone on isolated human tissue. Cardiovascular Research 1984;18:302-9.
138. Wood MA, Hess ML. Review: long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors. The American Journal of the Medical Sciences 1989;297:105-13.
139. Yusuf S, Simon R, Ellenberg S. Proceedings of "Methodological Issues in Overviews of Randomized Clinical Trials". Statistical Medicine 1987;6:217-409.
140. Yusuf S, Teo K. Inotropic agents increase mortality in patients with congestive heart failure. Circulation 1990;82(suppl III):III-673(abstr 2675).
141. Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients: a meta-analysis. European Journal of Clinical Pharmacology 1994;46:191-6.